Ibrutinib‐associated T‐cell pseudolymphoma

Ho, Albert K.; Koh, Xuan Qi; Liau, MeiQi May; Tan, Kong Bing; Tan, Char Loo

doi:10.1111/ced.13907

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other inflammatory reactions include lobular/septal panniculitis (21%) and rare reported cases of Sweet syndrome, pyogenic granuloma, pyoderma gangrenosum, granulomatous dermatitis, SJS, bullous pemphigoid, exfoliative toxin-positive staphylococcal scalded skin syndrome, and cutaneous lymphoid hyperplasia or cutaneous pseudolymphoma (CPL). 294,295,[300][301][302][303][304][305][306][307][308][309][310] Finally, secondary BCCs and cutaneous SCCs are seen in up to 4% of patients treated with ibrutinib. 299,311 Table 1 lists in detail the types of dermatologic toxicities associated with BTK inhibitors.…”

Section: Btk Inhibitorsmentioning

confidence: 99%

Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy

et al. 2021

View full text Add to dashboard Cite

Background: Advances in molecular biology and genetics have contributed to breakthrough treatments directed at specific pathways associated with the development of cancer. Small-molecule inhibitors (Nibs) aimed at a variety of cellular pathways have been efficacious; however, they are associated with significant dermatologic toxicities. Methods: We conducted a comprehensive review of dermatologic toxicities associated with Nibs categorized into the following five groups: (a) mitogen-activated protein kinase; (b) growth factor/multi-tyrosine kinase; (c) cell division/DNA repair; (d) signaling associated with myeloproliferative neoplasms; and (e) other signaling pathways. Prospective phase I, II, or III clinical trials, retrospective literature reviews, systematic reviews/meta-analyses, and case reviews/reports were included for analysis.Results: Dermatologic toxicities reviewed were associated with every class of Nibs and ranged from mild to severe or life-threatening adverse skin reactions.Inflammatory reactions manifesting as maculopapular, papulopustular/acneiform, and eczematous lesions were frequent types of dermatologic toxicities seen with Nibs.Squamous cell carcinoma with keratoacanthoma-like features was associated with a subset of Nibs. Substantial overlap in dermatologic toxicities was found between Nibs.Conclusions: Dermatologic toxicities from Nibs are diverse and may overlap between classes of Nibs. Recognition of the various types of toxicities from Nibs is critical for patient care in the era of "oncodermatology/dermatopathology."

show abstract

Section: Btk Inhibitorsmentioning

confidence: 99%

Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy

et al. 2021

View full text Add to dashboard Cite

show abstract

Ibrutinib

2019

Reactions Weekly

View full text Add to dashboard Cite

Drug‐induced cutaneous pseudolymphoma: A systematic review of the literature

et al. 2022

View full text Add to dashboard Cite

Drug‐induced cutaneous pseudolymphoma (CPL) is a common form of pseudolymphoma and there are numerous drugs associated with it. In this study, we performed a systematic review of the literature by searching PubMed/Medline and Embase databases to determine the most common drugs responsible for CPL and to define the demographic, clinical, histopathological and immunopathological characteristics of patients (updated on 30 December 2020). From 883 initially found articles, 56 studies (89 reported cases) were included. The mean age of patients was 54.4 ± 17.7 (ranging 8–86) years, and 46 (51.7%) were men. The median time interval between drug intake and CPL occurrence was 120 days (range 1–7300 days). The shortest median time interval between taking the drug and the onset of the disease was observed among patients taking antidepressants (60 days) (range 7–540) and the longest median time interval was observed in individuals using immunomodulators (300 days) (range 3–7300). The most‐reported drug categories causing CPL were anti‐hypertensives (17.9%), anticonvulsants (14.6%), monoclonal antibodies (13.4%) and antidepressants (11.2%). Moreover, the most common drugs were phenytoin (6.7%), amlodipine (5.6%), fluoxetine (5.6%) and carbamazepine (4.4%). Histopathological evaluation of 76 cases revealed 62 (81.5%) reports of T‐cell infiltrations. Furthermore, positive reports of CD4 (94.0%), CD8 (93.0%) and CD30 (87.5%) were noted. The lowest prevalence of CD30‐positive reports was observed among monoclonal antibodies. In conclusion, anti‐hypertensives, anti‐convulsants, monoclonal antibodies and anti‐depressants are the most common drugs responsible for CPL. It mostly presents in middle‐aged patients with almost no gender difference as pruritic papules, nodules and plaques.

show abstract

Ibrutinib‐associated T‐cell pseudolymphoma

Cited by 3 publications

References 4 publications

Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy

Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy

Ibrutinib

Drug‐induced cutaneous pseudolymphoma: A systematic review of the literature

Contact Info

Product

Resources

About